Asia

In-depth country-focused analysis on Asia's economic, political and operational risk environment,
complemented by detailed sector insight

Latest

Impact Of Teva's Actavis Generics Acquisition Declining

The Actavis Generics acquisition continues to define Teva Pharmaceutical Industries' recent sales improvements, but whilst the Q117 results represent a marked improvement over the prior year period, compared to Q416, there is a sharp downturn suggesting that the boost to sales is ending. Nonetheless, Teva maintains its confidence in its revenues for the remainder of the year, and the generic segment is still strong. Declining Copaxone sales provide evidence that this drug is finally succumbing to generic competition.

Views

Reports

×

Discuss your Custom Research needs

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

Thank you for your interest.

×

REQUEST A DEMO

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

Thank you for your interest

A member of the team will be in touch shortly to arrange a convenient time for your free demonstration and trial. If your enquiry is urgent, please email our Client Services team here.